See more : Evgen Pharma plc (EVG.L) Income Statement Analysis – Financial Results
Complete financial analysis of Cyxone AB (publ) (CYXO.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyxone AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Parag Milk Foods Limited (PARAGMILK.NS) Income Statement Analysis – Financial Results
- Guangdong Xinbao Electrical Appliances Holdings Co., Ltd (002705.SZ) Income Statement Analysis – Financial Results
- Punjab Chemicals and Crop Protection Limited (PUNJABCHEM.NS) Income Statement Analysis – Financial Results
- OPTiM Corporation (OTPMF) Income Statement Analysis – Financial Results
- Badaro No. 19 Ship Investment Company (155900.KS) Income Statement Analysis – Financial Results
Cyxone AB (publ) (CYXO.ST)
About Cyxone AB (publ)
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.15M | 6.40M | 0.00 | 0.00 | 26.57K | 1.00K | 0.00 | 21.00K | 21.00K |
| Cost of Revenue | 2.54M | 2.24M | 1.79M | 1.80M | 35.06M | 31.78M | 6.51M | 4.18M | 183.00K |
| Gross Profit | 2.61M | 4.16M | -1.79M | -1.80M | -35.03M | -31.78M | -6.51M | -4.16M | -162.00K |
| Gross Profit Ratio | 50.72% | 64.98% | 0.00% | 0.00% | -131,843.91% | -3,178,353.80% | 0.00% | -19,798.97% | -771.43% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 35.75M | 33.00M | 41.02M | 28.01M | 12.89M | 6.51M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.38M | 35.75M | 33.00M | 41.02M | 28.01M | 12.89M | 6.51M | 1.32M | 0.00 |
| Other Expenses | 0.00 | 6.42M | 11.79M | 7.86M | 7.16M | 2.54M | 2.31M | 0.00 | 0.00 |
| Operating Expenses | 28.21M | 42.17M | 44.79M | 48.88M | 35.17M | 15.44M | 8.82M | 1.32M | 0.00 |
| Cost & Expenses | 28.21M | 42.17M | 44.79M | 48.88M | 35.17M | 15.44M | 8.82M | 4.18M | 183.00K |
| Interest Income | 116.00K | 33.00K | 0.00 | 0.00 | 45.00 | 0.00 | 0.00 | 3.00K | 0.00 |
| Interest Expense | 37.00K | 33.00K | 0.00 | 0.00 | 273.00 | 300.00 | 69.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.54M | 2.24M | 1.79M | 1.80M | 1.79M | 956.04K | 22.00K | 4.00M | 324.00K |
| EBITDA | -20.41M | -40.19M | -43.23M | -47.20M | -33.37M | -30.83M | -8.80M | -3.00K | 162.00K |
| EBITDA Ratio | -396.54% | -628.13% | 0.00% | 0.00% | -125,601.32% | -1,512,270.00% | 0.00% | -14.29% | -771.43% |
| Operating Income | -21.66M | -42.44M | -45.05M | -49.00M | -35.17M | -15.43M | -8.82M | -4.16M | -162.00K |
| Operating Income Ratio | -420.77% | -663.15% | 0.00% | 0.00% | -132,354.43% | -1,543,400.00% | 0.00% | -19,798.95% | -771.43% |
| Total Other Income/Expenses | -1.33M | -297.00K | 17.00K | 0.00 | -228.00 | -16.35M | -498.00 | -165.62K | -162.00K |
| Income Before Tax | -22.99M | -42.47M | -45.03M | -49.00M | -35.17M | -15.43M | -8.82M | -4.16M | -162.00K |
| Income Before Tax Ratio | -446.52% | -663.67% | 0.00% | 0.00% | -132,355.29% | -1,543,400.00% | 0.00% | -19,817.26% | -771.43% |
| Income Tax Expense | 2.00K | -1.00K | 3.00K | -119.00K | 273.00 | -300.00 | 69.00 | 158.78K | -324.00K |
| Net Income | -22.99M | -42.47M | -45.03M | -49.00M | -35.17M | -15.43M | -8.82M | -4.16M | -162.00K |
| Net Income Ratio | -446.56% | -663.65% | 0.00% | 0.00% | -132,356.31% | -1,543,400.00% | 0.00% | -19,817.26% | -771.43% |
| EPS | -0.22 | -0.44 | -0.73 | -0.79 | -0.79 | -0.40 | -0.44 | -0.26 | -0.02 |
| EPS Diluted | -0.22 | -0.43 | -0.71 | -0.79 | -0.75 | -0.40 | -0.44 | -0.32 | -0.02 |
| Weighted Avg Shares Out | 104.50M | 95.77M | 61.42M | 61.79M | 44.61M | 38.61M | 20.02M | 15.98M | 6.63M |
| Weighted Avg Shares Out (Dil) | 106.17M | 98.44M | 63.68M | 61.79M | 46.73M | 38.61M | 20.02M | 12.93M | 6.63M |
Source: https://incomestatements.info
Category: Stock Reports